Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and Novartis

NEW YORK, September 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Sanofi (NYSE: SNY), Eli Lilly and Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), and Novartis AG (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On August 19, 2013, Johnson & Johnson announced that it has completed the acquisition of Aragon Pharmaceuticals, Inc. (Aragon). Johnson & Johnson reported that Aragon is a privately-held pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The Company also stated that Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, will manage the development of compounds from Aragon's androgen receptor antagonist program, including ARN-509, its lead androgen receptor signaling inhibitor. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/JNJ]

--

Sanofi Research Report

On August 26, 2013, Sanofi's vaccine division Sanofi Pasteur reported topline results of a large-scale, multi-center efficacy trial showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) compared with the standard dose of Fluzone vaccine in preventing influenza among patients aged 65 years and above. David P. Greenberg, M.D., Vice President of US Scientific and Medical Affairs at Sanofi Pasteur, stated, "This efficacy trial complements the previous evidence of superior immune responses for Fluzone High-Dose vaccine compared to Fluzone vaccine and reaffirms the Phase III safety data in this population that were the basis for FDA licensure of Fluzone High-Dose vaccine in 2009." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/SNY]

--

Eli Lilly and Company Research Report

On August 28, 2013, Eli Lilly and Company (Lilly) announced the election of Marschall S. Runge, M.D., Ph.D., as a member of its Board of Directors. Lilly reported that Runge will assume his position on September 1, 2013. John Lechleiter, Ph.D., Chairman, President, and CEO of Lilly, commented, "Dr. Runge brings to the Lilly board a broad background in health care, with extensive experience as a practicing physician, clinical researcher, and dean of a major academic medical institution. His appreciation of the importance of scientific research, coupled with his first-hand experience in patient care, will help Lilly deliver on its commitment to discover and develop innovative medicines that make a difference for patients in need." The Full Research Report on Eli Lilly and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/LLY]

--

AbbVie Inc. Research Report

On August 27, 2013, AbbVie Inc. (AbbVie) announced that Richard A. Gonzalez, Chairman and CEO, and Scott Brun, M.D., Vice President of Pharmaceutical Development, will participate in the upcoming Morgan Stanley Global Healthcare Conference. According to the Company, the event will be held on Tuesday, September 10, 2013. AbbVie reported that Gonzalez and Brun will participate in the question and answer session at 11:55 a.m. Central Time. The Company added that the live audio webcast can be accessed through its Investor Relations website. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/ABBV]

--

Novartis AG Research Report

On August 20, 2013, Novartis AG (Novartis) announced that its BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM) has received a breakthrough therapy designation from the US Food and Drug Administration (FDA). Timothy Wright, M.D., Global Head of Development at Novartis Pharmaceuticals, said, "BYM338 is the third example this year of Novartis' leadership in bringing breakthrough therapies to patients reinforcing our commitment to innovation addressing significant unmet medical needs and enhancing the lives of patients." Wright added, "With no effective therapies currently available for sIBM, bimagrumab has the potential to be the first real option for patients with this condition." The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/NVS]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors' Reports